Abin da Bachem's Flat Share Performance ke faɗi Game da Peptide CDMOs

Abin da Bachem's Flat Share Performance ke faɗi Game da Peptide CDMOs

Me yasa Ayyukan Rarraba Rarraunan Wakilci don Ƙimar Rarraba- Abokin Hulɗa

Haɓaka kudaden shiga galibi ana ɗaukar su ta hanyar haɗaɗɗun da ke faɗi kaɗan game da shirin ku. Ayyukan haɓaka-lokaci yana faɗaɗa tare da bututun bututu kuma yana cinye ƙarfin ƙarami, m increments; Samar da API na kasuwanci ya dogara da ingantattun layukan da ke gudana a barga mai amfani. Mai siyarwa na iya buga lambar girma mai ƙarfi yayin da ɓangaren da kuke buƙata ke yin kwangila - da sama, ya kasance.

kashe kudi alkawari ne, ba iyawa ba. Ƙarfin da aka sanar yana buƙatar ƙaddamarwa, cancanta, da ma'aikata kafin ya iya sakin kayan. Babban hannun jari na peptide CDMO na duniya ya kai shekaru biyar mafi girma a cikin 2026, ketare kusan USD 2.4 biliyan a tsakiyar shekara, amma ƙaƙƙarfan ɗauri shine hazaka - tsarin sunadarai, lyophilization injiniya, QA/QC - maimakon karfe.

Ƙididdiga masu amfani sun kasance jimillar, ba na sirri ba. US peptide CDMO iya aiki a kusan 78-85% in 2026, Maƙarƙashiya a cikin aikin GLP-1 na kasuwanci - sama da matakin da jinkirin da ke haifar da buƙatu ya fara buga lokutan asibiti., kasa da m 90% bakin kofa inda kwalabe na ƙasa ke haifar da haɗari mai inganci. Babu ƙarshen wannan rukunin ba ya gaya muku ko ku ramin akwai.

Babu ɗayan waɗannan da ke sa manyan dillalai marasa zaɓi. Don shirye-shiryen API na kasuwanci mai ƙarfi, babban sawun tsari mai fa'ida da samar da wurare da yawa, sikelin sau da yawa yana da yanke hukunci. Batun ya fi kunkuntar: Girman hasashe ne game da shirin ku, ba gamawa ba. ginshiƙai huɗu da ke ƙasa su ne yadda kuke gwada shi.

Matrix Matrix don Ƙimar Ƙimar Hudu

Tsarin da ke ƙasa an gina shi don kimanta mai samar da peptide - yana ɗaukar ƙimar mai siyarwa azaman girma huɗu waɗanda za'a iya tabbatarwa da kansu.. Ma'auni na kuɗi baya bayyana azaman ma'auni, domin babu wani adadi da zai maye gurbin daya daga cikinsu.

Kwayoyin cuta

Me yake amsawa

Shaida ta farko

Nauyin da aka ba da shawarar (mataki-dogara)

Daidaitaccen inganci

Shin wannan rukunin zai dace da na ƙarshe??

CoA na musamman tare da nazarin orthogonal; Multi-lot Trend bayanai; sabawa da rikodin CAPA

30-40% (mafi girma ga asibiti da wadata wadata)

Bayyanar iya aiki

Shin ƙarfin gaske ne, m, kuma nawa?

Bayyana iyawar matakin da aka raba; bayanan bakin ciki na kasa; ajiya da SLA sharuddan

20-30% (mafi girma ga shirye-shirye na ƙarshen zamani)

Zurfin fasaha

Kuna iya yin wannan jeri?

Takamaiman warware matsalar-jeri; hanya da dabarun tsarkakewa; karatun ka'idoji

20-30% (mafi girma ga hadaddun ko gyara peptides)

Sakamakon abokin ciniki

Shin kun yi shi a baya, kuma me ya faru?

Bita tarihi; m shirye-shirye; canja wurin daidaito; bayan sa hannu akan bayanin farashi

15-25%

Ma'aunin nauyi yana canzawa tare da matakin shirin: Binciken gano ya kamata ya yi nauyi zurfin fasaha da juyawa, yayin da shirye-shiryen ba da damar IND da na kasuwanci yakamata suyi nauyin daidaiton inganci da bayyana iya aiki da yawa sosai. Abin da bai kamata ya canza ba shine buƙatun shaida akan duka huɗun.

Daidaiton Inganci da Ƙaƙwalwar Lutu-zuwa-Lot - Tabbatarwa, Ba Buri ba

Daidaituwar inganci yana nufin jeren samar da nau'ikan peptide iri ɗaya a cikin ƙayyadaddun iyaka don ainihi, tsarki, rashin tsarki profile, da halayen da suka dace da aiki. Ba maganar niyya ba ce. rubuce ne, dukiyar da za a iya gani na tsarin sarrafawa.

Takardun da ke ɗauke da shaidar

Takaddun shaida na bincike yana da amfani kawai kamar ƙayyadaddun sa: CoA yana da alaƙa da ainihin adadin da kuka karɓa, kuma ana iya karanta bayanan da ke ƙasa maimakon taƙaitawa? Juya-lokaci HPLC shine daidaitaccen karantawa mai tsabta, yawanci gano a 214-220 nm, amma chromatogram, shafi, kuma gradient ya kamata a bayyane - ba kawai kashi ɗaya ba. Tabbacin ainihin asali ya fito ne daga ESI-MS ko MALDI-MS da aka ɗaure zuwa wuri ɗaya. Dangane da yanayin amfani, kwamitin sakin na iya mikawa ga ruwa da abun ciki, sauran kaushi a karkashin ICH Q3C(R9), endotoxin ta USP ⟨85⟩ gwaji, haihuwa, da kuma nazarin amino acid.

Ya kamata a bayyana ƙayyadaddun ƙayyadaddun bayanai a cikin nau'ikan nau'ikan abubuwan da masu gudanarwa ke tsammanin - ainihi, tsarki, kazanta, abun ciki ko ƙarfi, tare da halayen physicochemical masu dacewa - bin ƙa'idodin ƙayyadaddun ICH Q6B. A cikin EU, ta EMA jagora game da haɓakawa da kera peptides na roba, karba Disamba 2025 kuma tasiri 1 Yuni 2026, yana saita takamaiman tsammanin peptide don tsari, halayyar, ƙayyadaddun bayanai, da sarrafa nazari. Abokin tarayya wanda ya tsara shirin ku akan wannan tsarin yana nuna iko; wanda ba zai iya ba yana kwatanta niyya.

Abin da yawa-zuwa-yawa a zahiri ke nufi

Daidaituwa ƙungiya ce, ba lamba ba. Karatun jerin tsarki 95%, 92%, 98%, 88% fadin kuri'a masu zuwa ba tare da bayani ba kerarrewar hayaniya ba - siginar sarrafawa ce. Tambaya mai fa'ida ba shine “menene tsarkin ku ba?"amma" nuna mani kuri'a biyar a jere na kwatankwacin peptide, gefe da gefe.”

Halaye biyu sun raba tsattsauran masu siye da masu bege. Kiyaye kowane takamaiman takaddun tsari kuma a ɗauke shi azaman wurin bayanai, ba PDF ɗin da za a iya zubarwa ba. Sa'an nan kwatanta kowane sabon kuri'a da kuri'a na tarihin ku - tsarki, sawun yatsa mafi girma na sakandare, halayyar lokacin riƙewa - maimakon jigon kanun takardar shaidar. Don shirye-shiryen da aka ɗaure, kunshin da ke ba da damar IND yawanci yana gabatar da nazarin tsari a cikin akalla kuri'a uku a jere, tare da daidaiton kashi-kashi na yanki tsakanin kusan ± 1.0% da madaidaicin sawun yatsa na ƙazanta.

Lissafin tabbatarwa

Tambaya

Amsa mai karfi

Amsa mara ƙarfi

CoA takamaiman

Lamba mai yawa akan vial, shiryawa zamewa, da daidaiton satifiket; raw chromatogram yanzu

Taƙaitaccen kashi na tsafta kawai

Orthogonality

RP-HPLC da ESI-MS ko MALDI-MS, duka biyun daura da kuri'a

"Tsarki ≥98%" ba tare da bakan ba

Multi-lot data

Kuri'a biyar masu kwatankwacinsu, m band, barga mai ƙazantacce

Ba a bayar da bayanan yanayin yanayin ba

Gudanar da karkacewa

Bayanan sarrafawa, Binciken OOS, Rufe CAPA tare da kwanakin

Tabbacin baki kawai

Ƙarfin Ƙarfin Ƙarfin Ƙarfafa Peptide - Lambobi daban-daban guda biyar da ake kira "Irin"

Bayyanar iyawa yana nufin mai bayarwa yana raba abin da aka sanar da abin da aka shigar, abin da ya cancanta daga abin da ke samuwa a gare ku, kuma zai iya yin bambanci a rubuce. Ga mafi yawan masu siye wannan shine mafi girman rata tsakanin bene da kwangila.

Tambarin suna, shigar, m, aikata

Peptide Synthesis Ƙarfin ba adadi ɗaya ba ne. Nemi shi a cikin matakai.

Mataki

Abin da ake nufi

Abin da ya dace a gare ku

Tambarin suna / sanar

Zane niyya, sau da yawa ana bayyanawa a cikin sanarwar manema labarai

Babu wani abu a cikin kwangilar shekara

An shigar

Kayayyakin jiki a wurin

Babu komai sai an cancanta

GMP-cancantar

Cancanta don nau'in inganci mai dacewa da hanyar saki

Mai yuwuwar amfani, idan ba a yi rajista ba

Abokin ciniki-ƙaddara

Ana ba da izini ga shirin ku, girman tsari, da ranar saki

Lamba daya tilo da ta shafi tsarin tafiyarku

Mai sayarwa da ke ba da amsa kawai a matakin farantin suna ba lallai ba ne ya ɓace - yawancin ƙungiyoyi ba sa buga ƙididdiga masu rarrafe.. Tambayi ta wata hanya - ingancin amsar ita ce siginar.

Ƙaƙƙarfan ƙwanƙwasa wanda ya kafa ainihin rufin

Ƙarfin haɗaɗɗiyar ba kasafai ba ne ainihin ƙuntatawa. Don yawancin hadaddun ko manyan peptides, Girman da za a iya bayarwa ana sarrafa shi ta hanyar shiri na baya-bayan nan na HPLC - lissafin shafi, wuce ƙidaya, diamita - da lyophilization Peptides na roba kayan aiki, dawo da sauran ƙarfi, ajiya mai sanyi, da samuwan suite na nazari. Prep-HPLC suite count da diamita ginshiƙi sune mafi yawan wakili kai tsaye don fitarwa na matakin asibiti mai amfani fiye da ƙarar reactor.

⚠️ Gargadi: Domin amfani a tsakiyar 80% kewayo yana barin ɗan rahusa, ajiye ramin gaba sanar maimakon m iya aiki ɗaya ne daga cikin kurakuran saye na gama-gari - kuma mafi tsada - a cikin shirye-shiryen peptide.

Juya iyawa zuwa alkawari na kwangila

Ƙarfin yana zama abin dogaro ne kawai lokacin da aka rubuta shi cikin takaddun gudanarwa. Gaskiyar lokacin jagora na farko: ajiyar iya aiki a manyan peptide CDMOs yanzu yana gudana a cikin 18– wata 24 kewayo don aikin sikelin kasuwanci, fiye da ƙa'idodin watanni 6-12 na 2019-2021.

Yarjejeniyar inganci yana bayyana alhakin in ba haka ba barsu zuwa inganta matakin-aikin: batch records, gwajin saki, rikodin riƙewa, haƙƙin tantancewa, canza iko, karkacewa rufewa, da tallafi na tsari. Jadawalin matakin sabis yana ƙididdige aiki - kan-lokaci-cikakken bayarwa, aiwatar da dama-farko, lokutan rufewa, lokacin saki, amsawar haɓakawa - kuma yana faɗin abin da ke faruwa lokacin da aka rasa kofa. Alamar kasuwanci ta gama gari don kan lokaci, in-cikakken bayarwa shine 95% ko mafi girma, tare da gyara da aka ayyana a cikin kwangila maimakon yin shawarwari bayan gazawar. Ci gaba da kasuwanci harshe yana rufe redundancy, madadin kaya, da ƙuntatawa a takamaiman rukunin yanar gizon mai suna a cikin shawarar ku.

Idan shirin ku yana ɗaukar haɗari na gaske, ƙwararriyar hanya ta sakandare ba alamar rashin amincewa ba ce - shine daidaitaccen tsarin samar da peptide mai jurewa., kuma nasa ne kafin yakin farko, ba bayan jinkirin farko ba. Abokan haɗin gwiwa waɗanda ke tallafawa ci gaban tsarin peptide daga zaɓin hanya ta hanyar haɓakawa zai iya tattauna ci gaba tare da iya aiki. Samuwar Peptide

Lissafin tabbatarwa

Tambaya

Amsa mai karfi

Amsa mara ƙarfi

Bayyana iya aiki

Amfani na yanzu, lokacin fadadawa, da kuma matsayin slot, matakin da matakin

Adadin juzu'i na reactor ba tare da matsayin cancanta ba

Wurin shigar da rufi

Matsalolin ƙasa mai suna: prep-HPLC ginshikan, lyophilizers, dawo da sauran ƙarfi

"Karfin mu ba shine cikas ba"

Sharuɗɗan ajiya

Ma'anar ramin da aka rubuta, abubuwan da ake bukata, sharuddan sokewa

Ramin da aka kwatanta da baki a matsayin "samuwa yawanci"

Zurfin Fasaha - Inda "Za Mu Iya Yi" Ya Zama Shaida

Zurfin fasaha yana nufin iyawar da aka nuna don magance takamaiman matsaloli na jeri, ba kataloji na nau'ikan dauki ba. Bambance-bambancen yana da mahimmanci saboda peptides da ke kasawa ba su da sauƙi.

Adadin gwajin matakin-jere-jere

Za a iya gwada zurfin zurfi akan takamaiman azuzuwan wahala: dogayen sarkoki; ɓangarorin haɗuwa-mai yiwuwa ko hydrophobic waɗanda ke ƙin haɗawa da tsarkakewa; gada disulfide da yawa suna buƙatar nadawa mai sarrafa iskar oxygen; cyclization da stapling sunadarai; sauran abubuwan da ba na halitta ba da kuma D-amino acid; da conjugates na peptide zuwa furotin, kayatarwa, ko polymer. Rarraba isomers da gogewa ta hanyar samfuran shine ikon kansa - akai-akai wanda ke yanke shawarar ko shirin ya dace da lokacin sa..

Sikeli ya zama dole don aikin API na kasuwanci mai ƙarfi - ƙaƙƙarfan babban ɗakin SPPS tare da tsarkakewa da kayan aikin nazari babban alƙawarin babban jari ne.. Ba shaida ba ne cewa za a iya yin jerin abubuwan ku. Zaɓin hanya, guduro da kuma loading dabarun, kima hadarin rashin tsarki, kuma tsare-tsaren tsarkakewa hukunce-hukuncen jeri ne, kuma ana samun nasara ko akasarin shirye-shirye akan su.

Ƙididdigar ilimin kimiyya kamar yadda ake karanta zurfin ilimin kimiyya

Tambayi yadda shirin taswirori kan jagorar da ta dace. Jagorar EMA synthetic-peptide ya ƙunshi tsari, halayyar, ƙayyadaddun bayanai, da sarrafa nazari a cikin takamaiman sharuddan peptide. ICH Q6B ƙa'idodin ƙayyadaddun bayanai ayyana nau'ikan halayen da ke bayan dabarar saki mai karewa, kuma Ina Q3C(R9) akan sauran kaushi yana saita iyakoki waɗanda masana'antar peptide ke bi ta yau da kullun da aka ba da kundin ƙarfi. Mai sayarwa wanda ke tattauna waɗannan a hankali yana kwatanta sarrafawa; wanda ya karkata zuwa harshen talla yana bayyana rashinsa.

Ko sinadarai yana gudana akan ingantaccen lokaci mai ƙarfi, microbial fermentation, ko hanyar haɗaɗɗiyar hanya yakamata ta bi daga jerin maimakon dandamali da aka fi so. A al'ada peptide kira abokin tarayya wanda ke aiki a cikin duka biyun - kuma a cikin azuzuwan gyare-gyare 300+ zaɓuɓɓukan rukuni-rukuni - na iya zaɓar hanyar da kwayoyin ke buƙata. Mai siyarwa da aka kulle cikin dandamali ɗaya zai tura peptide ɗin ku ta cikinsa ba tare da la'akari da shi ba.

CTA: Yi jerin da ya gaza a wani wuri? Aika jerin da takamaiman yanayin gazawa - nazarin fasaha na hanya da dabarun tsarkakewa ya fi amfani fiye da ƙasida mai iyawa..

Lissafin tabbatarwa

Tambaya

Amsa mai karfi

Amsa mara ƙarfi

Ajin wahala

Mai suna kwatankwacin shirye-shirye, tare da jerin halaye da aka bayyana

"Muna yin kowane irin peptides"

Hanyoyi na hanya

Zaɓin dalili na SPPS, fermentation, ko matasan da aka ɗaure da jeri

An bayyana fifikon dandamali azaman tsoho

Karatun ka'idoji

Tattaunawa ta musamman game da tsammanin EMA da nau'ikan halayen ICH

Generic "muna goyan bayan yin rajistar tsari"

Sakamakon Abokin ciniki - Takardun da Zaku Iya Tabbatarwa

Ƙarshe na ƙarshe yana maye gurbin da'awar da bayanai. Shi ne mafi arha don dubawa kuma wanda aka fi tsallakewa saboda neman shi na iya jin gaba. Yi la'akari da shi azaman ƙwazo maimakon: kuna tabbatar da bayanan, ba ƙalubalanci niyya ba.

Tarihin bita ya bugu da ƙididdiga na takaddun shaida

Nemi tarihin bita maimakon ƙidayar takaddun shaida: shirye-shirye mai suna inda aka duba dabarun sarrafa ƙazanta na mai kaya da karɓa, a wanne kasuwanni, menene rashi tambayoyi aka yi, da yadda aka amsa su. Ƙididdigar takaddun shaida sun bayyana aikin takarda; rashi-da-amsa tarihin yana bayyana iyawa a ƙarƙashin bincike. Ƙarin sigina shine sawun ɗab'i - aikin da aka yi bita a cikin shekaru uku da suka gabata yana nuna haɗin peptides tare da tsayi mai kama., hydrophobicity, ko kuma hadaddun gyarawa.

Tambayoyin da aka ambata waɗanda ke tattare da haɗari na gaske

Kiran tunani yana ba da tabbaci saboda suna yin tambayoyi masu ƙarfafawa. Hudu mafi kyau:

  1. Yaya daidai lokacin canja wuri na asali da jadawalin lokaci-lokaci na farko da zarar an fara ainihin bayanai da takaddun takaddun?

  2. Shin mai ba da kaya ya yi ƙarfin matakin matakin wurin ko abubuwan da ke da alaƙa da wuri don kare shirin haɓakawa?

  3. Yadda aka saba, LABARI, da canje-canjen sarrafawa da aka sarrafa lokacin da shirin ke ƙarƙashin matsin aiki?

  4. Wanne farashi ko nauyi ne kawai ya bayyana bayan kwangila - aikin nazari, tabbatarwa, ajiya?

Tambaya ta huɗu ita ce wacce ta fi dacewa ta canza shawara: ci gaban nazari, tabbatarwa, kuma ajiya shine inda tsammanin kasafin kuɗi ya fi motsawa bayan kwangila. Mai kaya wanda ya riga ya kwashe waɗannan abubuwan ya gudanar da shirye-shirye a baya, kuma baya koyo akan naku.

Matsayin nazari shima yana da mahimmanci. Ƙungiyoyin da ke gudanar da gwajin peptide da nazari tare da masana'antu suna gayyatar binciken bayanan sakin nasu - matsayin da kuke so daga abokin tarayya wanda takardar shaidar ku za ku dogara da shi..

Lissafin tabbatarwa

Tambaya

Amsa mai karfi

Amsa mara ƙarfi

Kwatankwacin shirye-shirye

takamaiman jeri da aka bayyana ta aji, tare da sakamako

Tamburan da ba a san su ba ba tare da cikakkun bayanai ba

Bita tarihi

Kasuwanni mai suna, Tambayoyin kasawa da aka taso da amsa

An jera ƙidayar takaddun shaida

Dole-Dole, Tutoci masu ja, da Katin Ƙimar Kiwon Kai

Abubuwan da ake buƙata - tafiya idan ba a same su ba: musamman musamman, takaddun shaida marasa daidaituwa tare da bayanan nazari na orthogonal don kuri'a da za ku yi amfani da su; yarjejeniya mai inganci wacce ke rufe bayanan batch, canza iko, karkacewa rufewa, da haƙƙin tantancewa; takamaiman shafin da layin da zai samar da kayan ku; tuntuɓar fasaha mai suna tare da hukuma akan hanya; kuma, don aikin matakin asibiti, batch bayanai a jere a jere tare da tabbatattun sawun yatsu na ƙazanta.

Jajayen tutoci - bincika kafin a ci gaba: rashin iya suna ainihin shafin, layi, ko shirye-shiryen kwatankwacin kwanan nan; m shawarwari game da kasa batches, iya aiki, ko ƙarin aikin tabbatarwa; "ƙarshe-zuwa-ƙarshe" da'awar da ke ɓoye matakai na ɓangare na uku; masu amfani da tunani suna kwatanta abubuwan mamaki na marigayi akan sabawa, tsarawa, ko takardun shaida; ƙididdiga masu tsabta waɗanda ke tafiya a kan kuri'a ba tare da bayani ba.

Haƙuri gibba - farashin daidai: tsawon lokacin jagora a ƙaramin gwani, sau da yawa ana biya diyya ta hanyar amsawar fasaha cikin sauri; kunkuntar sawun tsari, karbuwa don ganowa da kuma shirye-shirye na musamman; kasa aiki da kai, akai-akai biya ta hanyar kai tsaye zuwa ga masana kimiyya masu gudanar da yakin ku.

Yanzu ci. Ƙimar abokan hulɗa da aka zaɓa daga 1 ku 5 akan kowane layi, daidaita layuka zuwa matakin shirinku kafin ku cika su. Ma'aunin nauyi, ba danyen maki ba, su ne abin da mafi yawan masu saye ke samun kuskure.

Ma'auni

Mataki

Ci (1– 5)

CoA-takamaiman Lot tare da ƙididdigar ƙididdiga da bayanai masu tasowa da yawa

Daidaitaccen inganci

karkata, OOS, da kuma tsarin CAPA

Daidaitaccen inganci

Ƙarfin da aka bayyana matakin ta matakin

Bayyanar iya aiki

An gano magudanar ruwa a ƙasa

Bayyanar iya aiki

Yarjejeniyar inganci da SLA tare da ma'aunin ma'auni

Bayyanar iya aiki

An nuna kwatankwacin ajin wahala da tunanin hanya

Zurfin fasaha

Karatun karatu na tsari akan tsammanin EMA/ICH

Zurfin fasaha

Bita tarihi, m shirye-shirye, da daidaiton lokacin canja wuri

Sakamakon abokin ciniki

Ƙa'idar fassarar ɗaya tana da mahimmanci fiye da jimlar: maki na 4 ko 5 a kan zurfin fasaha tare da a 2 akan daidaiton inganci shine bayanin martaba mafi haɗari a cikin tebur. Yana bayyana mai siyar da ke da ikon yin kamfen na farko mai ban sha'awa kuma ba zai iya sake bugawa ba. Nauyi daidai.

Abin da za a fara yi

Key Takeaway: Hasashen birgima, yanke shawara mai tushe biyu da aka rubuta, da kuma duba takardun - a cikin wannan tsari - warware ƙarin haɗarin mai siyarwa fiye da kowace dabarar tattaunawa da aka yi amfani da ita daga baya.

Fara da hasashen mirgina. Bukatar peptide taswira a cikin watanni 18-24 masu zuwa - girman batch da nau'ikan ingancin da aka haɗa - kuma a ba da jerin sunayen masu samar da wannan hoton kafin neman fa'ida.. Bayyanar hasashen hasashen ita ce hanya mafi inganci don samun amsa ta gaske akan samuwar ramin, saboda yana barin mai siyarwa ya amsa wani tsari na kankare maimakon hasashe.

Sa'an nan kuma yanke shawara mai amfani biyu da gangan, kafin karfin karfin ya tilasta shi. Yanke shawarar waɗanne shirye-shirye ne za su iya jure wa tushe guda ɗaya, sannan ku cancanci hanyar sakandare ga waɗanda ba za su iya ba. Cancantar mai siyarwa akan ƙayyadaddun ƙayyadaddun farashi fiye da cancantar ɗaya akan jadawalin ku.

Daga karshe, takardun duba kafin wani abu: takamaiman takaddun shaida, Trend bayanai a kan m peptides, da ingantacciyar yarjejeniya da samfuran SLA waɗanda zasu jagoranci dangantakar. Yawancin haɗarin mai kaya ana iya gani a cikin takardu, kuma ana iya duba takardu ba tare da ziyartar shafin ko odar siyayya ba.

Lokacin da kuka shirya don matsawa daga kimantawa zuwa kisa, abokan hulɗa waɗanda za su iya magana da hanya, sikelin, da dabarun saki a cikin tattaunawa guda suna sa canjin ya zama guntu. Canje-canjen MOL yana gudanar da tattaunawar gaba ɗaya al'ada peptide kira, tabbaci na nazari, bakararre masana'antu, da haɓakawa - ko kawo takamaiman jerin abubuwan da ke hana shi zuwa tattaunawar fasaha. Wannan hanya ce mai sauri zuwa yanke shawara fiye da wani zagaye na nunin faifai na iyawa.

admin Avatar

Jinling Liu

Tsari R&D da Masanin Fasahar Masana'antu Ƙwararrun Ƙwararru: Tsari ma'auni, kimiyyar kore, inganta yawan amfanin ƙasa, Yarda da samar da GMP.

Bayanan martaba: Jinling Liu ya kware a tsarin fassarar magungunan peptide daga ma'aunin dakin gwaje-gwaje (milligram darajar) don samar da sikelin kasuwanci (darajar kilogram). Ta himmatu wajen rage yawan farashin samar da peptide da rage gurɓacewar muhalli ta hanyar inganta yanayin ɓarkewa., inganta rabo daga reagents na tari, da kuma gabatar da fasahar haɗin gwiwar ci gaba da gudana. Ta jagoranci inganta ayyukan peptide da yawa, cikin nasarar cimma ƙananan farashi, samar da taro mai tsabta a ma'aunin kilogiram 100.

An Duba Gaskiyar & Jagoran Edita
Reviewed by: Kwararrun Maudu'i
Raba wannan labarin
Gida Bincika Whatsapp Ayyuka Samfura